查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832353

腦腫瘤診斷和治療市場（按治療類型、診斷類型、最終用戶和腫瘤類型分類）—2025-2032 年全球預測

Brain Tumor Diagnosis & Treatment Market by Treatment Type, Diagnosis Type, End User, Tumor Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到2032年腦瘤診斷和治療市場規模將成長至31.1億美元，複合年成長率為7.04%。

主要市場統計數據
基準年2024年 18億美元
預計2025年 19.3億美元
預測年份：2032年 31.1億美元
複合年成長率（%） 7.04%

對不斷變化的臨床、技術和操作環境進行清晰而令人信服的介紹，重塑全球腦腫瘤診斷和治療途徑。

腦瘤的診斷和治療正處於快速科學創新與複雜臨床決策的交會點，需要臨床醫生、研究人員和醫療系統領導者的嚴謹指導。分子生物學、影像技術和治療治療方法的進步提升了診斷的準確性和治療方法方案，但同時也帶來了患者選擇、手術流程、報銷和監管協調等方面的全新複雜性。因此，相關人員必須平衡新治療方法的前景與現實限制，例如設施的可及性、跨學科合作以及長期療效的衡量。

在過去十年中，臨床診療方案已從「一刀切」的策略轉變為更個人化的方案，將分子診斷與先進的影像學和標靶治療相結合。因此，第一線醫療越來越依賴整合的診斷途徑，這些途徑結合了切片檢查技術、影像學方法和分子檢測，以獲得對腫瘤生物學的更深入的理解。這種演變對臨床工作流程、實驗室實踐和跨學科培訓有著直接的影響，為供應商和醫療系統重新思考其服務提供模式創造了機會。

展望未來，將診斷準確性轉化為持續的治療效益將取決於診斷、外科手術、全身性治療和支持性護理等各環節的協調改進。積極投資跨職能能力（從混合手術室和立體定位平台到分子病理學和數據整合）的醫療系統將更有能力運用新證據並改善患者預後。本介紹涵蓋轉型變革、資費相關影響、細分考量、區域動態、競爭洞察以及為領導者在不斷變化的市場環境中提供切實可行的建議。

全面檢驗診斷、治療和數位融合創新，重新定義腦腫瘤治療和臨床決策的精準途徑

在診斷、治療和數據主導醫療服務整合發展的推動下，腦腫瘤生態系統正在經歷變革。影像學已從解剖學描繪轉向功能和分子表徵，從而能夠更早發現治療反應和復發情況，並制定更精準的手術計劃。同時，基因表現分析、次世代定序和基於PCR的檢測，正在重新定義腫瘤的分類和預後，並在治療方法選擇方面發揮越來越重要的作用。

在治療方面，分子標靶藥物和免疫療法正在改變治療流程。標靶治療，例如Bevacizumab、mTOR抑制劑和蛋白酪氨酸激酶抑制劑，為特定腫瘤亞型提供精準的、基於機制的治療；而免疫療法，例如嵌合抗原受體T細胞療法、查核點抑制劑和癌症疫苗，則致力於實現持久的抗腫瘤免疫力。放射療法創新涵蓋體外照射、立體定位放射放射線手術和近距離放射治療，可增強局部控制，同時降低繼發性毒性。外科手術技術也不斷進步，影像導引切除術和微創立體定位手術改善了最大切除範圍和功能保留之間的平衡。

數位轉型正在擴大這些臨床創新。人工智慧和機器學習增強了影像解讀能力，實現了分割自動化，並支援預後建模，從而縮短了診斷時間，並實現了更個人化的監測策略。臨床和基因組數據的互通性支持了多學科腫瘤委員會，並加速了轉化研究。總而言之，這些轉變正在創造一個精準診斷和多學科護理融合以提供個人化治療方法的格局——這也引發了關於公平獲取、報銷政策以及大規模實現這些效益所需的勞動力能力的緊迫問題。

對近期貿易政策調整和關稅動態如何影響供應鏈、籌資策略以及腦癌治療的臨床應用進行批判性分析

貿易和關稅政策的變化對臨床供應鏈、研究採購和設備供應產生連鎖反應，顯著影響腦腫瘤治療的發展。進口關稅和監管要求的變化增加了採購先進成像硬體、立體定位設備和專用耗材的成本和複雜性，同時也影響了分子診斷和次世代定序儀工作流程中使用的試劑的供應和定價。這些下游壓力可能會增加診斷實驗室和影像中心的工作量，延遲資本升級，並限制在常規臨床實踐中採用新診斷方法的速度。

除了直接採購影響外，關稅主導的轉變可能會重組國內外供應商之間的夥伴關係，並促使製造商重新評估生產基地和供應鏈冗餘。為此，醫療保健提供者和研發機構可能會優先考慮策略採購，延長庫存前置作業時間，並實現供應商關係多元化，以降低供應風險。重要的是，關稅引發的成本壓力也可能影響與付款人的價格談判，減緩資本密集型治療平台的採用，並推動系統層面的決策，即在何處集中專科服務以實現規模經濟。

對於研究網路和臨床試驗而言，生物材料、設備和臨床實驗套件跨境流動的變化可能會造成物流障礙，影響臨床試驗的啟動和樣本處理的時間表。因此，研究申辦方和研究人員必須預見貿易相關的意外事件，並將其納入研究規劃和預算中。總體而言，關稅動態是獲取和創新的非臨床決定因素，凸顯了積極主動的供應鏈策略、政策參與和自適應採購模式的必要性，以保持改善腦腫瘤診斷和治療的勢頭。

全面的細分驅動整合，主導治療方式、診斷工作流程、最終用戶和腫瘤亞型的細微差別，以指導策略優先排序

細分感知觀點揭示了投資和營運重點，這將最有效地加速整個診斷和治療途徑中以患者為中心的結果。依治療類型，有化療、免疫療法、放射線治療、手術和標靶治療。化療包括聯合治療、亞硝脲和Temozolomide；免疫療法包括 CAR T 細胞療法、查核點抑制劑和疫苗；放射線治療包括近距離放射治療、體外放射線治療和立體定位放射線手術。標靶治療方案包括Bevacizumab、mTOR 抑制劑和蛋白酪氨酸激酶抑制劑，每種藥物的作用機制不同，需要協調一致的診斷策略和結果測量。

診斷細分進一步明確了臨床工作流程和實驗室需求。根據診斷類型，診斷流程包括切片檢查、影像學和分子診斷。切片檢查技術涵蓋從開放性切片檢查到立體定位切片檢查；影像學包括電腦斷層掃描、磁振造影造影、正子斷層掃描和超音波；分子診斷則結合了基因表現分析、次世代定序和基於PCR的檢測，為治療方法選擇和預後預測提供分子背景資訊。這些診斷方式與治療選擇和監測範式密切相關，並為多學科護理路徑的設計提供參考。

最終用戶細分有助於了解服務的交付地點和容量限制。根據最終用戶，醫療服務由診斷中心、醫院、研究機構和專科診所提供，每個機構的基礎設施、人員配備模式和報銷介面均不相同。基於腫瘤類型的細分凸顯了臨床異質性。基於腫瘤類型的主要分類包括神經膠質瘤、髓母細胞瘤、腦膜瘤和腦下垂體瘤。神經膠質瘤包括星狀細胞瘤、膠質母細胞瘤和寡樹突膠質瘤，而腦下垂體瘤的分類包括顱咽瘤和腦下垂體腺瘤。根據腫瘤亞型量身訂做治療方法和診斷強度對於最佳化結果和資源分配至關重要，這凸顯了從診斷到縱向監測的綜合護理途徑的必要性。

影響全球衛生系統取得和實施的區域採用模式、基礎設施動態和政策背景的細緻評估

區域動態對醫療體系中診斷創新和治療方式的採用、擴展和報銷方式有重大影響。美洲的臨床生態系統涵蓋大型綜合學術醫療中心和社區醫院，為技術採用、集中式專科服務和多機構合作創造了多樣化的途徑。該地區的籌資策略和報銷模式決定了先進成像、立體定位平台和分子檢測融入標準實踐的速度。歐洲、中東和非洲是一個多元化的地區，法律規範、醫療體系資金籌措和基礎設施方面的差異導致了不同的採用曲線。雖然高容量中心分散在各個地區，但在某些地區，獲得複雜診斷和專科程序的機會仍然有限，這促使人們依賴轉診網路和區域卓越中心。

受國際臨床研究和跨境合作參與度提升的推動，亞太地區臨床基礎設施以及診斷劑和醫療設備的國內生產能力正在快速擴張。在許多亞太市場，公共對三級醫療保健的投資正與私部門的參與度不斷提升相結合，加速了技術應用。在整個地區，臨床和基因組數據互通性網路、勞動力發展和遠端醫療的增強，正在成為擴大專科醫生就診管道的推動因素。了解區域差異對於制定實施策略、協調商業性參與以及建立兼顧當地監管、經濟和臨床現實的合作至關重要。

深入審查競爭動態、夥伴關係策略和創新重點領域，這將決定哪些公司將推動臨床應用和服務發展

腦腫瘤診斷和治療生態系統的競爭態勢反映了老牌生物醫學公司、新興生物技術創新者、專業設備製造商和診斷實驗室的整合。大型醫療設備和製藥公司繼續利用其規模、監管經驗和分銷網路，支援診斷影像平台、立體定位系統和已通過核准療法的廣泛臨床部署。同時，規模較小的專業公司和學術衍生公司正在推動精準放射治療規劃、分子檢測開發和新型免疫療法等利基領域的創新，並經常與大型公司合作，推進後期開發和商業化。

隨著治療決策越來越依賴生物標記和影像資訊的整合，診斷服務提供者和治療開發商之間的策略合作變得越來越重要。將實驗室開發的檢測方法、次世代定序和臨床試驗網路結合起來的夥伴關係，有助於患者分層，並加速轉化研發流程。智慧財產權策略、監管途徑導航和真實世界證據生成是致力於持續臨床應用的公司的關鍵差異化因素。此外，委外研發機構、專業服務供應商和區域代理商在臨床試驗物流和複雜技術的本地化部署方面發揮關鍵作用。

相關人員在評估競爭對手活動時，應專注於積極投資的領域，例如分子診斷平台、人工智慧影像解決方案、立體定位放射放射線手術系統以及細胞療法生產能力。擁有強大臨床證據基礎、清晰的報銷策略和可擴展服務模式的公司將最有能力將創新轉化為廣泛的臨床效用。最終，成功取決於商業策略是否與臨床工作流程、付款人要求以及神經腫瘤科設施的營運現狀一致。

領導者可以採取一系列切實可行的優先策略行動，以確保診斷準確性和治療方法創新轉化為公平的臨床影響

行業領導者必須採取積極主動的策略，將技術能力轉化為持續的臨床價值和公平的可及性。首先，投資於整合診療途徑，將分子分析、高階影像和多學科臨床決策融入無縫銜接的工作流程。其次，透過多元化專用耗材、試劑和資本設備的供應商關係，並制定緊急時應對計畫以因應政策變化或物流限制造成的採購中斷，從而增強供應鏈的韌性。

第三，我們將與學術中心、社區醫療保健提供者和產業建立合作夥伴關係，以擴大患者獲得專科診斷和新型療法的管道，並進行更大規模、更具代表性的臨床研究。第四，我們將設計臨床和現實世界研究，以證明比較有效性、以患者為中心的結果以及與報銷決策相關的成本影響，從而使證據生成與付款人的期望保持一致。第五，我們將投資於勞動力發展和跨學科培訓，使臨床醫生、病理學家、放射科醫生和實驗室工作人員能夠操作複雜的診斷演算法，並安全有效地提供多學科護理。

最後，採用考慮公平和經濟的以患者為中心的商業化策略，例如分層交付模式、遠端醫療支援網路和集中高複雜度護理的區域卓越中心，將使相關人員能夠將科學進步轉化為可擴展的臨床效益，同時管理營運風險並加強整個衛生系統的相關人員合作。

我們的分析基於一種透明的、基於臨床的方法，結合了主要專家訪談、系統文獻綜合和多源檢驗

本分析背後的調查方法結合了多方面的定性和定量分析技術，以確保研究結果全面且檢驗。主要研究包括對臨床專家、實驗室主任、醫院採購負責人和行業高管進行結構化訪談，以獲取關於診斷工作流程、治療決策和營運限制的第一手觀點。次要研究則包括對同儕審查文獻、臨床指南更新、監管溝通和公共衛生政策文件的系統性回顧，以揭示臨床實踐和技術的發展軌跡。

資料合成採用三角測量技術，將主要訪談結果與已發表的證據和產業揭露資訊進行比對。與領域專家進行的檢驗輪次確保對技術能力、監管途徑和營運可行性的解讀能夠反映當前的實踐模式。本研究指南倫理考量，包括保護訪談期間共用的機密資訊以及對機密業務事項進行去身分化處理。調查方法的局限性包括不同地區數據粒度的差異以及新治療方法的依證的不斷演變。

總體而言，該調查方法優先考慮透明度、交叉檢驗和臨床有效性，所產生的分析結果可支持腦腫瘤診斷和治療領域的營運決策、策略規劃和進一步的研究合作。

簡潔而明確的結論，結合了實現診斷進步、治療方法多樣化和改善患者結果所需的系統性要求。

本執行摘要概述了診斷創新、治療多樣化和系統性因素如何塑造現代腦腫瘤治療。分子診斷和影像技術的進步提高了診斷準確性並為治療分層提供了資訊，而標靶治療、免疫治療和放射治療的改進則拓展了治療選擇。雖然這些發展為改善療效提供了機會，但安全有效的治療需要在基礎設施、人才培養和證據生成方面進行協同投資。

貿易政策動態和區域基礎設施差異等外部因素會影響實施的速度和公平性，進而影響採購、研究物流以及獲得先進醫療服務的管道。競爭動態凸顯，那些整合診斷和治療價值提案、展示臨床和經濟價值並建立可擴展服務交付模式的營業單位將取得成功。切實可行的建議主要包括：建立綜合路徑、增強供應鏈韌性、培育協作網路、使證據生成與付款人需求相一致，以及致力於勞動力和醫療服務可及性計劃。

最後，實現改善腦腫瘤治療的願景需要臨床醫生、衛生系統、產業和政策制定者的共同行動。積極主動地將技術能力與營運準備和公平的交付模式相結合的相關人員，將最有能力將創新轉化為有意義的患者利益和永續的系統影響。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合人工智慧驅動的放射組學分析平台，實現準確的腫瘤表徵和治療計劃
  • 擴大血液液態生物檢體，以早期發現和監測膠質母細胞瘤進展
  • 採用術中螢光引導成像技術改善腫瘤切除邊緣
  • 針對突變型 EGFRvIII 和其他新型膠質瘤抗原的 CAR T 細胞療法的開發
  • 神經腫瘤學中下一代質子治療系統的監管核准和商業化策略
  • 遠距遠端醫療平台在腦腫瘤治療的應用

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章腦腫瘤診斷與治療市場（依治療類型）

  • 化療
    • 聯合治療
    • 亞硝脲類
    • Temozolomide
  • 免疫療法
    • CAR-T細胞療法
    • 查核點抑制劑
    • 疫苗
  • 放射線治療
    • 近距離放射治療
    • 體外放射治療
    • 立體定位放射線手術
  • 外科手術
  • 標靶治療
    • Bevacizumab
    • Mtor抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章腦腫瘤診斷與治療市場（依診斷類型）

  • 切片檢查
    • 開放切片檢查
    • 立體定位切片檢查
  • 影像學
    • 電腦斷層掃描
    • 磁振造影
    • 正子斷層掃描
    • 超音波
  • 分子診斷
    • 基因表現
    • 次世代定序
    • 基於PCR的檢測

第 10 章腦腫瘤診斷與治療市場（依最終使用者）

  • 診斷中心
  • 醫院
  • 研究機構
  • 專科診所

第11章腦腫瘤診斷與治療市場（依腫瘤類型）

  • 膠質瘤
    • 星狀細胞瘤
    • 神經膠母細胞瘤
    • 寡樹突膠質瘤
  • 髓母細胞瘤
  • 腦膜瘤
  • 腦下垂體瘤
    • 顱咽瘤
    • 腦下垂體腺瘤

第12章腦腫瘤診斷與治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章腦腫瘤診斷與治療市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國腦瘤診斷與治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Siemens Healthineers AG
    • GE Healthcare LLC
    • Koninklijke Philips NV
    • Elekta AB
    • Varian Medical Systems, Inc.
    • Accuray Incorporated
    • Roche Holding AG
    • Novartis AG
    • Merck & Co., Inc.
    • Novocure Limited
Product Code: MRR-437D459585B5

The Brain Tumor Diagnosis & Treatment Market is projected to grow by USD 3.11 billion at a CAGR of 7.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.80 billion
Estimated Year [2025] USD 1.93 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 7.04%

A clear and compelling introduction to the evolving clinical, technological, and operational landscape reshaping brain tumor diagnosis and treatment pathways globally

Brain tumor diagnosis and treatment sit at the intersection of rapid scientific innovation and complex clinical decision-making, demanding rigorous navigation by clinicians, researchers, and health system leaders. Advances in molecular biology, imaging technology, and therapeutic modalities have expanded diagnostic precision and therapeutic options, yet they have also introduced new layers of complexity around patient selection, procedural workflows, reimbursement, and regulatory alignment. Consequently, stakeholders must reconcile the promise of novel interventions with real-world constraints such as equipment access, interdisciplinary coordination, and long-term outcome measurement.

Over the past decade, the clinical narrative has shifted from one-size-fits-all strategies toward more personalized approaches that integrate molecular insights with advanced imaging and targeted therapies. As a result, frontline practice increasingly relies on integrated diagnostic pathways that combine biopsy techniques, imaging modalities, and molecular assays to produce a nuanced understanding of tumor biology. This evolution has immediate implications for clinical workflows, laboratory operations, and cross-disciplinary training, and it creates opportunities for vendors and health systems to reimagine service delivery models.

Looking ahead, the ability to translate diagnostic precision into durable therapeutic benefit will hinge on coordinated improvements across diagnostics, surgery, systemic therapies, and supportive care. Health systems that proactively invest in cross-functional capabilities-ranging from hybrid operating suites and stereotactic platforms to molecular pathology and data integration-will be better positioned to operationalize emerging evidence and improve patient outcomes. This introduction frames the subsequent sections, which explore transformational shifts, tariff-related impacts, segmentation insights, regional dynamics, competitive considerations, and actionable recommendations for leaders navigating this evolving landscape.

An in-depth examination of converging diagnostic, therapeutic, and digital innovations that are redefining precision pathways for brain tumor care and clinical decision-making

The brain tumor ecosystem is undergoing transformative shifts driven by converging advances in diagnostics, therapeutics, and data-driven care delivery. Imaging has moved beyond anatomical depiction to functional and molecular characterization, enabling earlier detection of treatment response and recurrence and permitting more nuanced surgical planning. Parallel advances in molecular diagnostics, including gene expression profiling, next generation sequencing, and PCR-based assays, have redefined tumor classification and prognostication, and they increasingly inform therapeutic selection.

On the therapeutic front, targeted agents and immunotherapies are changing the treatment algorithm. Targeted Therapy options such as bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors provide mechanistic precision for select tumor subtypes, while immunotherapy approaches including CAR T-cell therapy, checkpoint inhibitors, and cancer vaccines are extending lines of inquiry into durable anti-tumor immunity. Radiotherapy innovation, spanning external beam modalities, stereotactic radiosurgery, and brachytherapy, is enhancing focal control with reduced collateral toxicity. Surgical technology has likewise advanced, with image-guided resection and minimally invasive stereotactic approaches improving the balance between maximal resection and functional preservation.

Digital transformation is amplifying these clinical innovations. Artificial intelligence and machine learning augment imaging interpretation, automate segmentation, and support prognostic modeling, thereby shortening diagnostic timelines and enabling more personalized surveillance strategies. Interoperability of clinical and genomic data supports multidisciplinary tumor boards and accelerates translational research. Taken together, these shifts are creating a landscape in which precision diagnostics and multimodal treatment converge to offer individualized pathways, while simultaneously raising pressing questions about equitable access, reimbursement policy, and the workforce competencies required to realize these benefits at scale.

A rigorous analysis of how recent trade policy adjustments and tariff dynamics are influencing supply chains, procurement strategies, and clinical adoption in brain tumor care

Policy shifts in trade and tariffs can produce ripple effects across clinical supply chains, research procurement, and device availability that materially influence the delivery of brain tumor care. Changes to import duties and regulatory requirements raise the cost and complexity of sourcing advanced imaging hardware, stereotactic equipment, and specialized disposables, while also affecting the availability and pricing of reagents used in molecular diagnostics and next generation sequencing workflows. These downstream pressures can increase operational burden for diagnostic laboratories and imaging centers, delay capital upgrades, and constrain the pace at which new diagnostic modalities are adopted in routine clinical practice.

Beyond direct procurement impacts, tariff-driven shifts can reshape partnerships between domestic and international suppliers, prompting manufacturers to reevaluate production footprints and supply chain redundancy. In response, providers and research institutions may prioritize strategic procurement, develop longer inventory lead times, and diversify vendor relationships to mitigate supply risk. Importantly, tariff-induced cost pressures can also influence pricing negotiations with payers, slow adoption of capital-intensive therapeutic platforms, and prompt system-level decisions around where specialized services are centralized to achieve economies of scale.

For research networks and clinical trials, changes to cross-border movement of biological materials, instrumentation, and diagnostic kits can introduce logistical hurdles that affect trial initiation and sample processing timelines. Consequently, research sponsors and clinical investigators must anticipate and incorporate trade-related contingencies into study design and budgeting. In the aggregate, tariff dynamics act as a non-clinical determinant of access and innovation, underscoring the need for proactive supply chain strategies, policy engagement, and adaptive procurement models to preserve the momentum of improvements in brain tumor diagnosis and treatment.

A comprehensive segmentation-driven synthesis connecting treatment modalities, diagnostic workflows, end users, and tumor subtype nuances to guide strategic prioritization

A segmentation-aware perspective illuminates where investment and operational focus will most effectively accelerate patient-centered outcomes across diagnostic and therapeutic pathways. Based on Treatment Type, the clinical landscape encompasses Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy; within these categories, Chemotherapy pathways include combination therapies, nitrosoureas, and temozolomide, while Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccines, and Radiotherapy comprises brachytherapy, external beam radiotherapy, and stereotactic radiosurgery. Targeted Therapy options span bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors, each offering distinct mechanisms that require aligned diagnostic strategies and outcome measurement.

Diagnostic segmentation further clarifies clinical workflows and laboratory needs. Based on Diagnosis Type, the diagnostic continuum includes biopsy, imaging, and molecular diagnostics; biopsy procedures range from open biopsy to stereotactic biopsy, imaging modalities include computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound, and molecular diagnostics incorporate gene expression profiling, next generation sequencing, and PCR-based assays to provide molecular context for therapeutic choice and prognostication. These diagnostic modalities interact closely with treatment selection and surveillance paradigms and inform the design of multidisciplinary care pathways.

End user segmentation highlights where services are delivered and where capacity constraints may emerge. Based on End User, care is provided across diagnostic centers, hospitals, research institutes, and specialty clinics, each with distinct infrastructure, staffing models, and reimbursement interfaces. Tumor type segmentation brings clinical heterogeneity into focus. Based on Tumor Type, the principal categories include glioma, medulloblastoma, meningioma, and pituitary tumor; glioma includes astrocytoma, glioblastoma, and oligodendroglioma, while pituitary tumor distinctions include craniopharyngioma and pituitary adenoma. Aligning therapeutic modalities and diagnostic intensity with tumor subtype is essential for optimizing outcomes and resource allocation, and it emphasizes the need for integrated care pathways that span diagnosis through long-term surveillance.

A nuanced assessment of regional adoption patterns, infrastructure dynamics, and policy contexts shaping access and implementation across global health systems

Regional dynamics exert a profound influence on how diagnostic innovations and therapeutic modalities are adopted, scaled, and reimbursed across health systems. In the Americas, clinical ecosystems vary from large integrated academic medical centers to community hospitals, producing diverse pathways for technology adoption, centralized specialty services, and multisite research collaboration; procurement strategies and reimbursement models in this region shape the pace at which advanced imaging, stereotactic platforms, and molecular testing are integrated into standard practice. Europe, Middle East & Africa presents a heterogeneous picture in which regulatory frameworks, health system financing, and infrastructure disparities create differentiated adoption curves; pockets of high-capacity centers coexist with regions where access to complex diagnostics and specialty surgery remains limited, prompting a reliance on referral networks and regional centers of excellence.

Asia-Pacific demonstrates rapid capacity expansion in both clinical infrastructure and domestic manufacturing of diagnostic reagents and medical devices, accompanied by growing participation in international clinical research and cross-border collaboration. The convergence of public investment in tertiary healthcare and increased private sector involvement in many Asia-Pacific markets accelerates the diffusion of technology, while also creating varied payer landscapes that affect affordability and access. Across all regions, interoperability of clinical and genomic data, workforce training, and telemedicine-enhanced networks act as enablers for expanding access to specialist expertise. Understanding regional nuances is critical for tailoring implementation strategies, aligning commercial engagement, and structuring collaborative research that accounts for local regulatory, economic, and clinical realities.

An incisive review of competitive dynamics, partnership strategies, and innovation focus areas that determine which companies will drive clinical adoption and service evolution

Competitive dynamics in the brain tumor diagnosis and treatment ecosystem reflect a blend of established biomedical firms, emerging biotechnology innovators, specialized device manufacturers, and diagnostic laboratories. Large medical device and pharmaceutical companies continue to leverage scale, regulatory experience, and distribution networks to support wide clinical deployment of imaging platforms, stereotactic systems, and approved therapeutics. At the same time, smaller specialized firms and academic spin-outs drive innovation in niche areas such as precision radiotherapy planning, molecular assay development, and novel immunotherapeutic constructs, often partnering with larger organizations to progress late-stage development and commercialization.

Strategic collaborations between diagnostics providers and therapeutic developers are becoming increasingly important as treatment decisions rely on integrated biomarker and imaging information. Partnerships that bridge laboratory-developed tests, next generation sequencing, and clinical trial networks facilitate patient stratification and accelerate translational pipelines. Intellectual property strategy, regulatory pathway navigation, and real-world evidence generation are key differentiators for companies that seek durable clinical adoption. Moreover, contract research organizations, specialty service providers, and regional distributors play a pivotal role in enabling clinical trial logistics and localized deployment of complex technologies.

For stakeholders evaluating competitor behavior, attention should focus on areas of active investment such as molecular diagnostics platforms, AI-enabled imaging solutions, stereotactic radiosurgery systems, and cell therapy manufacturing capacity. Companies that combine robust clinical evidence generation with clear reimbursement strategies and scalable service models are best positioned to transform innovations into widespread clinical utility. Ultimately, success hinges on aligning commercial strategy with clinical workflows, payer requirements, and the operational realities of centers delivering neuro-oncology care.

A set of practical and prioritized strategic actions that leaders can implement to ensure diagnostic precision and therapeutic innovation translate into equitable clinical impact

Industry leaders must adopt proactive strategies to translate technological potential into consistent clinical value and equitable access. First, invest in integrated diagnostic-to-therapy pathways that bring molecular profiling, advanced imaging, and multidisciplinary clinical decision-making into seamless workflows; prioritizing interoperability and data standards will streamline case review and accelerate therapy selection. Second, strengthen supply chain resilience by diversifying vendor relationships for specialized consumables, reagents, and capital equipment, and by developing contingency plans that address procurement disruptions caused by policy shifts or logistical constraints.

Third, forge collaborative partnerships across academic centers, community providers, and industry to broaden patient access to specialized diagnostics and novel therapies, while also enabling larger, more representative clinical studies. Fourth, align evidence generation with payer expectations by designing clinical and real-world studies that demonstrate comparative effectiveness, patient-centered outcomes, and cost implications relevant to reimbursement decisions. Fifth, invest in workforce development and cross-disciplinary training to ensure clinicians, pathologists, radiologists, and laboratory staff can operationalize complex diagnostic algorithms and deliver multimodal treatments safely and effectively.

Finally, adopt a patient-centric commercialization strategy that considers equity and affordability, including tiered delivery models, telemedicine-enabled networks, and regional centers of excellence that concentrate high-complexity care. By implementing these actions, leaders can convert scientific advances into scalable clinical benefits while managing operational risk and strengthening stakeholder alignment across health systems.

A transparent and clinically grounded methodology combining primary expert interviews, systematic literature synthesis, and multi-source validation to underpin the analysis

The research approach underpinning this analysis combined multifaceted qualitative and quantitative methods to ensure comprehensive and validated findings. Primary research comprised structured interviews with clinical specialists, laboratory directors, hospital procurement leaders, and industry executives to capture firsthand perspectives on diagnostic workflows, therapeutic decision-making, and operational constraints. Secondary research involved systematic review of peer-reviewed literature, clinical guideline updates, regulatory communications, and public health policy documents to contextualize clinical practice and technology trajectories.

Data synthesis employed triangulation techniques to reconcile insights from primary interviews with published evidence and industry disclosures. Validation rounds with subject matter experts ensured that interpretations of technological capability, regulatory pathways, and operational feasibility reflected current practice patterns. Ethical considerations guided the research, including protection of confidential information shared during interviews and de-identification of sensitive operational details. Limitations of the methodology included variability in regional data granularity and evolving evidence bases for emerging therapies; where appropriate, findings emphasize directional insights and implementation considerations rather than definitive long-term projections.

Overall, the methodology prioritized transparency, cross-validation, and clinical relevance to produce an analysis that supports operational decision-making, strategic planning, and further research collaboration within the brain tumor diagnosis and treatment domain.

A concise and decisive conclusion tying together diagnostic advances, therapeutic diversification, and systemic imperatives required to realize improved patient outcomes

This executive summary synthesizes how diagnostic innovation, therapeutic diversification, and systemic factors jointly shape contemporary brain tumor care. Advances in molecular diagnostics and imaging have enhanced diagnostic precision and informed treatment stratification, while targeted therapies, immunotherapies, and radiotherapy refinements are expanding therapeutic options. These developments create opportunities for improved outcomes but also necessitate coordinated investments in infrastructure, workforce training, and evidence generation to ensure safe and effective adoption.

External forces such as trade policy dynamics and regional infrastructure disparities influence the speed and equity of implementation, affecting procurement, research logistics, and access to advanced care. Competitive dynamics reveal that successful entities will be those that integrate diagnostic and therapeutic value propositions, demonstrate clinical and economic value, and build scalable service delivery models. Actionable recommendations center on creating integrated pathways, strengthening supply chain resilience, fostering collaborative networks, aligning evidence generation with payer needs, and committing to workforce and access initiatives.

In closing, realizing the promise of improved brain tumor care will require coordinated action across clinicians, health systems, industry, and policymakers. Stakeholders who proactively align technological capability with operational readiness and equitable delivery models will be best positioned to convert innovation into meaningful patient benefit and sustainable system impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven radiomics analysis platforms for precise tumor characterization and treatment planning
  • 5.2. Expansion of blood-based liquid biopsy assays for early detection and monitoring of glioblastoma progression
  • 5.3. Adoption of intraoperative fluorescence-guided imaging techniques to improve tumor resection margins
  • 5.4. Development of CAR T cell therapies targeting mutant EGFRvIII and other novel glioma antigens
  • 5.5. Regulatory approvals and commercialization strategies for next-generation proton therapy systems in neuro-oncology
  • 5.6. Implementation of telemedicine platforms for remote multidisciplinary tumor board consultations in brain cancer care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Combination Therapies
    • 8.1.2. Nitrosoureas
    • 8.1.3. Temozolomide
  • 8.2. Immunotherapy
    • 8.2.1. Car T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccines
  • 8.3. Radiotherapy
    • 8.3.1. Brachytherapy
    • 8.3.2. External Beam Radiotherapy
    • 8.3.3. Stereotactic Radiosurgery
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Bevacizumab
    • 8.5.2. Mtor Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Brain Tumor Diagnosis & Treatment Market, by Diagnosis Type

  • 9.1. Biopsy
    • 9.1.1. Open Biopsy
    • 9.1.2. Stereotactic Biopsy
  • 9.2. Imaging
    • 9.2.1. Computed Tomography
    • 9.2.2. Magnetic Resonance Imaging
    • 9.2.3. Positron Emission Tomography
    • 9.2.4. Ultrasound
  • 9.3. Molecular Diagnostics
    • 9.3.1. Gene Expression Profiling
    • 9.3.2. Next Generation Sequencing
    • 9.3.3. Pcr-Based Assays

10. Brain Tumor Diagnosis & Treatment Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes
  • 10.4. Specialty Clinics

11. Brain Tumor Diagnosis & Treatment Market, by Tumor Type

  • 11.1. Glioma
    • 11.1.1. Astrocytoma
    • 11.1.2. Glioblastoma
    • 11.1.3. Oligodendroglioma
  • 11.2. Medulloblastoma
  • 11.3. Meningioma
  • 11.4. Pituitary Tumor
    • 11.4.1. Craniopharyngioma
    • 11.4.2. Pituitary Adenoma

12. Brain Tumor Diagnosis & Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Brain Tumor Diagnosis & Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Brain Tumor Diagnosis & Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Siemens Healthineers AG
    • 15.3.2. GE Healthcare LLC
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Elekta AB
    • 15.3.5. Varian Medical Systems, Inc.
    • 15.3.6. Accuray Incorporated
    • 15.3.7. Roche Holding AG
    • 15.3.8. Novartis AG
    • 15.3.9. Merck & Co., Inc.
    • 15.3.10. Novocure Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY RE